Social-media influencer Trisha Paytas lost 26 pounds [1] over a six-week period [2] while using a GLP-1 medication.
Paytas' experience highlights the growing trend of high-profile figures utilizing GLP-1 receptor agonists for weight management. As these medications become more widely discussed in popular culture, their impact on appetite regulation and long-term health remains a central point of public interest.
Paytas said the medication helped her control her appetite and allowed her to eat her favorite foods in moderation. She said this process was a way to become her healthiest self.
Reflecting on her history with food, Paytas said, "I grew up on fast food and processed foods. I've just always eaten out and always overate. Like, I've never felt full in my life."
She said that before the medication, she struggled with a constant desire to eat. "After I eat one meal, I already think of the next," Paytas said.
Paytas said the tool provided a sense of liberation in her health journey. "It’s freeing to have the tools to become my healthiest self," she said.
The influencer's weight loss of 26 pounds [1] occurred within the six-week window [2] leading up to her June 18, 2024, interview. She said that the medication addressed a lifelong struggle with satiety, the feeling of fullness after eating, which had previously made weight management difficult.
“"I've never felt full in my life."”
The public disclosure of GLP-1 use by influencers like Paytas reflects a shift in how weight-loss medications are perceived, moving from strictly clinical applications for diabetes to lifestyle tools for weight management. This visibility often increases consumer demand for these drugs, while simultaneously sparking debates regarding the accessibility and long-term effects of pharmacological appetite suppression.
